#

19-21 SEPTEMBER 2017 //

MARITIM PROARTE HOTEL, BERLIN

Register Now

Enquiry

#

Loading
  1. Registration & breakfast for Phacilitate Cell & Gene Therapy Europe 2017
  1. Close of session - Morning Coffee
  1. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 1

  2. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 1

  3. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 1

  4. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 1

  1. Track 2: R&D updates & emerging science: Engineered stem cells: the next great innovation wave in cell & gene therapy?

  2. Track 2: R&D updates & emerging science: Engineered stem cells: the next great innovation wave in cell & gene therapy?

  3. Track 2: R&D updates & emerging science: Engineered stem cells: the next great innovation wave in cell & gene therapy?

  4. Track 2: R&D updates & emerging science: Engineered stem cells: the next great innovation wave in cell & gene therapy?

  5. Track 2: R&D updates & emerging science: Engineered stem cells: the next great innovation wave in cell & gene therapy?

  1. Buffet lunch in the exhibition area
  1. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 2

  2. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 2

  3. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 2

  4. Track 1: Cell-based therapy business & innovation: Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 2

  1. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  2. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  3. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  4. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  5. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  6. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  7. Track 2: R&D updates & emerging science: Immuno-oncology: novel targets and innovative ways to induce a better immune response

  8. Track 2: R&D updates & emerging scienceImmuno-oncology: novel targets and innovative ways to induce a better immune response

  1. Afternoon Tea in the exhibition area
  1. Track 1: Cell-based therapy business & innovation / Track 3: Vector business & innovation: Meaningful de-risking strategies around ATMP raw and starting material quality and supply

  2. Track 1: Cell-based therapy business & innovation / Track 3: Vector business & innovation: Meaningful de-risking strategies around ATMP raw and starting material quality and supply

  3. Track 1: Cell-based therapy business & innovation / Track 3: Vector business & innovation: Meaningful de-risking strategies around ATMP raw and starting material quality and supply

  4. Questions for the speakers
  1. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  2. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  3. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  4. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  5. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  6. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  7. Track 2: R&D updates & emerging science, Emerging cellular immunotherapy: Attacking solid tumours

  1. Close of day 1, followed by a drinks reception
  1. Registration & breakfast for Phacilitate Cell & Gene Therapy Europe 2017
  1. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovationFinding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  2. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  3. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  4. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  1. Morning coffee in the exhibition area
  1. Track 1: Cell-based therapy business & innovation: Harnessing the cutting edge of automation to drive robust, cost effective cell-based therapy manufacturing at commercial scale

  2. Track 1: Cell-based therapy business & innovation: Harnessing the cutting edge of automation to drive robust, cost effective cell-based therapy manufacturing at commercial scale

  1. Buffet lunch in the exhibition area
  1. Track 1: Cell-based therapy business & innovation: What tools do cell therapy manufacturers need to deliver necessary time and cost savings in QC/release testing?

  2. Track 1: Cell-based therapy business & innovation: What tools do cell therapy manufacturers need to deliver necessary time and cost savings in QC/release testing?

  3. Track 1: Cell-based therapy business & innovation: What tools do cell therapy manufacturers need to deliver necessary time and cost savings in QC/release testing?

  1. Track 2: R&D updates & emerging science: Gene editing platforms

  2. Track 2: R&D updates & emerging scienceGene editing platforms

  3. Track 2: R&D updates & emerging science: Gene editing platforms

  4. Track 2: R&D updates & emerging science: Gene editing platforms

  5. Track 2: R&D updates & emerging science: Gene editing platforms

  6. Track 2: R&D updates & emerging science: Gene editing platforms

  1. Track 3: Vector business & innovationViral vector bioanalytics and Quality Control: Alleviating uncertainty through regulatory insight and technical innovation

  2. Track 3: Vector business & innovation: Viral vector bioanalytics and Quality Control: Alleviating uncertainty through regulatory insight and technical innovation

  3. Track 3: Vector business & innovation: How are next-generation viral vector engineering approaches addressing long-standing targeted delivery and safety concerns?

  4. Track 3: Vector business & innovation: How are next-generation viral vector engineering approaches addressing long-standing targeted delivery and safety concerns?

  5. Track 3: Vector business & innovation: How are next-generation viral vector engineering approaches addressing long-standing targeted delivery and safety concerns?

  1. Workshop Track: Biotech exit strategy boot camp part 2: IPO

  1. Afternoon Tea in the exhibition area
  1. Track 1: Cell-based therapy business & innovation / Track 3: Vector business & innovation: A shift in mindset? Integrated, end-to-end supply chain and support system planning to unlock European ATMP market potential

  2. Track 1: Cell-based therapy business & innovation / Track 3: Vector business & innovation: A shift in mindset? Integrated, end-to-end supply chain and support system planning to unlock European ATMP market potential

  1. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

  2. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

  3. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

  4. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

  5. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

  6. Track 2: R&D updates & emerging scienceOncolytic viruses and cancer vaccines: what is on the horizon?

  7. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

  8. Track 2: R&D updates & emerging science: Oncolytic viruses and cancer vaccines: what is on the horizon?

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad

Sponsors

  • #
  • #
  • #
  • #
  • TrakCel, Silver Sponsor at Cell & Gene Therapy Europe
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #